Clovis Oncology Company Profile (NASDAQ:CLVS)

About Clovis Oncology

Clovis Oncology, Inc. is a biopharmaceutical company focused on acquiring, developing and commercializing anti-cancer agents in the United States, Europe and other international markets. The Company is developing approximately three product candidates: Rociletinib, Rucaparib and Lucitanib. Rociletinib is an oral epidermal growth factor receptor (EGFR), mutant-selective covalent inhibitor that is under review with the United States and European regulatory authorities for the treatment of non-small cell lung cancer (NSCLC) in patients with activating EGFR mutations, as well as the resistance mutation, T790M. Rucaparib is an oral inhibitor of poly (ADP-ribose) polymerase (PARP) that is in advanced clinical development for the treatment of ovarian cancer. Lucitanib is an oral inhibitor of the tyrosine kinase activity of vascular endothelial growth factor receptors 1-3 (VEGFR1-3) and platelet-derived growth factor receptors alpha and beta (PDGFR a/b).

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Exchange: NASDAQ
• Symbol: CLVS
• CUSIP: 18946410

Key Metrics:

• Previous Close: $37.44
• 50 Day Moving Average: $24.67
• 200 Day Moving Average: $17.64
• 52-Week Range: $11.57 - $109.18
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -7.59
• P/E Growth: 0.00
• Market Cap: $1.44B
• Outstanding Shares: 38,501,000
• Beta: 1.98

Profitability:

• Return on Equity: -130.84%
• Return on Assets: -51.06%

Debt:

• Debt-to-Equity Ratio: 2.49%
• Current Ratio: 5.48%
• Quick Ratio: 5.48%

Additional Links:

• Visit Clovis Oncology's Official Website
• View CLVS on Google Finance
• View CLVS on Yahoo Finance
• View CLVS's Company Profile on Reuters
• Search for Clovis Oncology Inc. on Google

Companies Related to Clovis Oncology:

• Ultragenyx Pharmaceutical (NASDAQ:RARE)
• Sarepta Therapeutics (NASDAQ:SRPT)
• The Medicines (NASDAQ:MDCO)
• GW Pharmaceuticals PLC- (NASDAQ:GWPH)
• Bluebird Bio (NASDAQ:BLUE)
• Ariad Pharmaceuticals (NASDAQ:ARIA)
• Wright Medical Group (NASDAQ:WMGI)
• Insulet Corp. (NASDAQ:PODD)
• LifePoint Hospitals (NASDAQ:LPNT)
• INC Research Holdings (NASDAQ:INCR)

Earnings

Earnings History for Clovis Oncology (NASDAQ:CLVS)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
11/3/2016
8/8/2016	Q216	($2.13)	($2.07)			View	Listen
5/5/2016	Q116	($2.39)	($2.17)			View	Listen
2/25/2016	Q415	($2.44)	($3.12)			View	Listen
11/5/2015	Q315	($2.07)	($2.62)			View	Listen
8/6/2015	Q215	($1.99)	($2.10)	$1.17 million		View	Listen
5/6/2015	Q115	($1.82)	($1.86)	$13.60 million		View	Listen
2/25/2015	Q414	($1.30)	($1.62)			View	Listen
11/6/2014	Q314	($1.07)	($1.17)			View	Listen
8/7/2014	Q214	($0.96)	($1.03)		$13.60 million	View	Listen
5/8/2014	Q114	($0.85)	($0.91)		$13.60 million	View	Listen
2/27/2014	Q4	($0.78)	($0.92)			View	Listen
10/31/2013	Q313	($0.68)	($0.68)			View	Listen
8/1/2013	Q2 2013	($0.65)	($0.72)			View	Listen
5/7/2013	Q1 2013	($0.60)	($0.60)			View	Listen

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Clovis Oncology (NASDAQ:CLVS)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q3 2016	1	($2.04)	($2.04)	($2.04)
Q4 2016	1	($1.94)	($1.94)	($1.94)

(Data provided by Zacks Investment Research)

Dividends

Dividend History for Clovis Oncology (NASDAQ:CLVS)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Clovis Oncology (NASDAQ:CLVS)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
11/2/2015	Erle T. Mast	CFO	Sell	3,000	$105.56	$316,680.00
10/28/2015	Lindsey Rolfe	insider	Sell	4,000	$98.02	$392,080.00
10/15/2015	Gillian C Ivers-Read	Insider	Sell	3,000	$91.91	$275,730.00
10/5/2015	Lindsey Rolfe	insider	Sell	4,000	$93.04	$372,160.00
10/1/2015	Erle T. Mast	CFO	Sell	3,000	$90.22	$270,660.00
9/18/2015	Gillian C Ivers-Read	Insider	Sell	3,000	$112.56	$337,680.00
9/1/2015	Erle T. Mast	CFO	Sell	3,000	$79.51	$238,530.00
7/1/2015	Erle T Mast	CFO	Sell	3,000	$85.70	$257,100.00
6/1/2015	Erle T Mast	CFO	Sell	3,000	$88.78	$266,340.00
5/15/2015	M James Barrett	Director	Sell	2,424	$92.43	$224,050.32
4/1/2015	Erle T Mast	CFO	Sell	3,000	$71.25	$213,750.00
3/9/2015	Erle T Mast	CFO	Sell	9,000	$78.84	$709,560.00
3/5/2015	James C Blair	Director	Sell	8,528	$77.70	$662,625.60
1/16/2015	Steven L Hoerter	Insider	Sell	10,000	$67.00	$670,000.00
12/11/2013	Erle Mast	CFO	Sell	50,000	$52.78	$2,639,000.00
12/5/2013	Thorlef Spickschen	Director	Sell	9,000	$56.10	$504,900.00
6/5/2013	Andrew R Allen	Insider	Sell	22,594	$68.54	$1,548,592.76
6/4/2013	M James Barrett	Director	Sell	2,483	$70.80	$175,796.40
6/4/2013	Parters Vii L P Domain	Major Shareholder	Sell	159,192	$64.58	$10,280,619.36
6/4/2013	Steven L Hoerter	Insider	Sell	10,000	$73.06	$730,600.00
3/6/2013	Parters Vii L P Domain	Major Shareholder	Sell	250,000	$24.59	$6,147,500.00
8/16/2012	Edward J Mckinley	Director	Buy	9,701	$15.50	$150,365.50

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Clovis Oncology (NASDAQ:CLVS)

Date	Headline
	Moving Average Crossover Alert: Clovis Oncology (CLVS) (NASDAQ:CLVS) finance.yahoo.com - September 26 at 4:31 PM
	Clovis short sellers undaunted as stock price surges (NASDAQ:CLVS) feeds.reuters.com - September 26 at 4:28 PM
	Stocks notched another impressive showing today, with these three delivering exceptional gains (NASDAQ:CLVS) investorplace.com - September 23 at 3:40 PM
	2 Sizzling Hot Biotechnology Stocks: Exelixis, Inc. (EXEL), Clovis Oncology, Inc. (CLVS) - The Independent Republic (NASDAQ:CLVS) theindependentrepublic.com - September 23 at 9:24 AM
	Clovis Oncology Inc 20.7% Potential Upside Now Implied by Stifel (NASDAQ:CLVS) alltechnews.org - September 22 at 4:25 PM
	Active biotech company shares in the news: Clovis Oncology (NASDAQ:CLVS), Halozyme Therapeutics (NASDAQ ... - The Voice Registrar (NASDAQ:CLVS) voiceregistrar.com - September 22 at 9:52 AM
	Commit To Buy Clovis Oncology At $17.50, Earn 23.5% Annualized ... - Nasdaq (NASDAQ:CLVS) www.nasdaq.com - September 21 at 8:19 AM
	4 Stocks To Watch: CLVS, ERII, EXEL, GIMO (NASDAQ:CLVS) www.investing.com - September 16 at 5:42 AM
	Can The Uptrend Continue for Clovis Oncology (CLVS)? (NASDAQ:CLVS) finance.yahoo.com - September 15 at 9:41 PM
	Analysts Valuations For Two Stocks: SunPower Corporation ... - The Voice Registrar (NASDAQ:CLVS) voiceregistrar.com - September 15 at 4:39 PM
	Clovis Oncology, Inc. :CLVS-US: Earnings Analysis: Q2, 2016 By the Numbers : September 13, 2016 (NASDAQ:CLVS) www.capitalcube.com - September 14 at 8:31 AM
	Is Clovis Oncology Still a Strong Buy? (NASDAQ:CLVS) www.fool.com - September 12 at 12:21 PM
	Clovis Oncology Inc (NASDAQ:CLVS): Worth A Billion Dollars? - Market Exclusive (NASDAQ:CLVS) marketexclusive.com - September 10 at 4:04 PM
	Clovis Oncology Stock Jumps as FDA Skips Review Panel for New Cancer Drug (NASDAQ:CLVS) www.biospace.com - September 10 at 8:56 AM
	Clovis Oncology (CLVS) Reports FDA Doesn't Plan to Hold Advisory Committee Meeting on Rucaparib NDA (NASDAQ:CLVS) www.streetinsider.com - September 10 at 8:56 AM
	What’s The Meaning Of The FDA Skipping Panel Review Of Clovis Oncology Inc (NASDAQ:CLVS)’s Rucaparib? (NASDAQ:CLVS) marketexclusive.com - September 10 at 8:56 AM
	Shares Ticking Lower in Trade: Clovis Oncology, Inc. (NASDAQ:CLVS) - Post News (NASDAQ:CLVS) www.kentuckypostnews.com - September 9 at 4:09 PM
	What's The Meaning Of The FDA Skipping Panel Review Of Clovis ... - Market Exclusive (NASDAQ:CLVS) marketexclusive.com - September 9 at 4:09 PM
	Clovis' Rucaparib Not to Face FDA Advisory Panel, Stock Up (NASDAQ:CLVS) finance.yahoo.com - September 9 at 4:08 PM
	Gilead Sciences: What is PARP? (NASDAQ:CLVS) blogs.barrons.com - September 9 at 4:08 PM
	Why Clovis Oncology Inc. Is Soaring Today - Motley Fool (NASDAQ:CLVS) www.fool.com - September 9 at 9:05 AM
	Clovis Oncology (CLVS) in Focus: Stock Moves 15% Higher (NASDAQ:CLVS) finance.yahoo.com - September 9 at 9:05 AM
	Notable Thursday Option Activity: TAP, DDD, CLVS (NASDAQ:CLVS) www.stockoptionschannel.com - September 8 at 4:09 PM
	Clovis Oncology Inc. (CLVS) Has Broken Out To An 8-Month High (NASDAQ:CLVS) www.rttnews.com - September 8 at 4:09 PM
	Here's A Reason Why Clovis Oncology (CLVS) Stock Is Surging Today (NASDAQ:CLVS) www.thestreet.com - September 8 at 4:09 PM
	Clovis Oncology Up As FDA Skips Review Panel For New Drug (NASDAQ:CLVS) www.investors.com - September 8 at 4:09 PM
	Why Clovis Oncology Inc. Is Soaring Today (NASDAQ:CLVS) www.fool.com - September 8 at 1:24 PM
	Placing Clovis Oncology, Inc. (NASDAQ:CLVS) Shares Under the Microscope - Post News (NASDAQ:CLVS) www.kentuckypostnews.com - September 8 at 5:13 AM
	Kyle Bass Makes Huge Bet Against McDonald’s, Sells Off Clovis (NASDAQ:CLVS) www.insidermonkey.com - September 6 at 9:09 AM
	Stock Gapping Down Pre-Bell: Clovis Oncology, Inc. (NASDAQ:CLVS) - Post News (NASDAQ:CLVS) www.kentuckypostnews.com - September 2 at 4:04 PM
	News review of 2 biotech stocks: Clovis Oncology, Inc. (NASDAQ:CLVS), Navidea Biopharmaceuticals, Inc (NYSEMKT ... - The Voice Registrar (NASDAQ:CLVS) voiceregistrar.com - September 2 at 4:04 PM
	Analyst Reviews on Overbuying: Clovis Oncology Inc (NASDAQ:CLVS) - Post Registrar (NASDAQ:CLVS) postregistrar.com - September 2 at 9:05 AM
	Pfizer Inc. (NYSE:PFE) To Receive Higher Payment Than First Reported From Clovis (CLVS) (NASDAQ:CLVS) marketexclusive.com - September 1 at 11:29 AM
	Here’s Why Many Smart Money Investors Are Bullish on Clovis Oncology (NASDAQ:CLVS) feedproxy.google.com - August 31 at 11:28 AM
	Clovis Oncology (CLVS) Enters First Amended with Pfizer Over Licensing Agreement (NASDAQ:CLVS) www.streetinsider.com - August 31 at 9:04 AM
	CLOVIS ONCOLOGY, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement (NASDAQ:CLVS) biz.yahoo.com - August 31 at 9:04 AM
	Morning Movers: Clovis Amends Pfizer Agreement; H&R Block Tumbles (NASDAQ:CLVS) blogs.barrons.com - August 31 at 9:04 AM
	Trading the Biotech News: ImmunoCellular Therapeutics ... - The Voice Registrar (NASDAQ:CLVS) voiceregistrar.com - August 29 at 4:29 PM
	Clovis announces FDA application for accelerated approval of cancer drug (NASDAQ:CLVS) www.innovationews.com - August 25 at 4:18 PM
	5 Companies That Should Consider Kicking Their CEOs to the Curb (NASDAQ:CLVS) www.fool.com - August 25 at 9:13 AM
	Some strong economic data lifted stocks Tuesday, including these three (NASDAQ:CLVS) investorplace.com - August 24 at 4:16 PM
	Our Take On The Clovis Oncology Inc (CLVS) Announcement (NASDAQ:CLVS) feedproxy.google.com - August 24 at 3:06 PM
	Clovis Oncology, Inc. (NASDAQ: CLVS) announced today that the U. (NASDAQ:CLVS) www.thestreet.com - August 24 at 10:40 AM
	Clovis Oncology shares soar after FDA accepts cancer-drug application (NASDAQ:CLVS) bizwest.com - August 24 at 10:40 AM
	Why is Clovis Oncology’s (CLVS) Stock up 27%? (NASDAQ:CLVS) www.economiccalendar.com - August 24 at 10:40 AM
	Clovis Oncology Rockets as FDA Agrees to Priority Review of Rucaparib NDA (NASDAQ:CLVS) www.biospace.com - August 24 at 10:40 AM
	Clovis Oncology, Inc. (CLVS) Rockets on FDA Acceptance of New Drug Application (NASDAQ:CLVS) www.investorguide.com - August 24 at 10:40 AM
	How Analysts and Investors Are Chasing Clovis Higher and Higher, All Over Again (NASDAQ:CLVS) 247wallst.com - August 24 at 10:40 AM
	Here's a Reason Why Clovis Oncology (CLVS) Stock Climbed Today (NASDAQ:CLVS) www.thestreet.com - August 23 at 9:28 PM
	Clovis shares jump as FDA grants priority review to cancer treatment (NASDAQ:CLVS) www.marketwatch.com - August 23 at 9:28 PM

Social

Clovis Oncology (NASDAQ:CLVS) Chart for Tuesday, September, 27, 2016